Hativ® ELectrocardiogram Monitoring on Patients With Suspected Arrhythmia
Condition(s) studied
Investigational drug(s) / intervention(s)
Memo Patch continuous ECG: Continuous single-lead ECG monitoring for up to 7 consecutive days. Participants report the onset of symptoms using a mobile messaging chatbot or paper diary. For each reported symptomatic episode, a 20-minute ECG segment extending from 10 minutes before to 10 minutes after the reported onset is available for review.
Hativ handheld ECG: Handheld ECG monitoring using 10-second 6-lead recordings obtained at least twice daily and additionally whenever symptoms occur for 30 days. Recordings are transmitted through the companion smartphone application to a secure study server.
Study summary
HELP-A is a prospective, randomized, open-label, multicenter comparative-effectiveness trial comparing two ambulatory electrocardiographic monitoring strategies in adults with palpitations or dizziness and a nondiagnostic 12-lead ECG. A total of 588 participants are randomized 1:1 to 30-day intermittent handheld 6-lead ECG monitoring (Hativ) or up to 7 days of continuous single-lead patch ECG monitoring (Memo Patch). The primary endpoint is clinically informative symptom-rhythm correlation established with the initially assigned device by the 1-month follow-up visit. Participants without a symptom-rhythm correlation who remain symptomatic may undergo optional sequential monitoring with the alternative device after primary endpoint ascertainment. Clinical outcomes, arrhythmia-directed interventions, healthcare resource utilization, costs, and adverse events are assessed through 3 months.
Eligibility
Primary outcome measure(s)
- Clinically informative symptom-rhythm correlation with the initially assigned device by 1 month — From randomization through the 1-month follow-up visit
Proportion of randomized participants with at least one participant-confirmed typical symptomatic episode documented with an interpretable ECG using the initially assigned device by the 1-month follow-up visit and before optional sequential monitoring. Primary-endpoint success comprises either a positive symptom-rhythm correlation or a negative-only symptom-rhythm correlation. A positive correlation is a qualifying symptomatic episode with an interpretable ECG showing a rhythm finding judged by central adjudication to be temporally and clinically concordant with that episode. A negative-only correlation requires at least one qualifying symptomatic episode with an interpretable ECG showing no concordant rhythm finding and no positive correlation by the 1-month visit.
Trial sites (4)
| Facility | City | Region | Status |
|---|---|---|---|
| Chonnam National University Hospital | Gwangju | Dong-gu Jaebongro 42 | Recruiting |
| Wonju Severance Christian Hospital | Wŏnju | Gangwon-do | Recruiting |
| Hallym University Dongtan Sacred Heart Hospital | Gyeonggi-do | Hwaseong-si Keunjaebong-gil 7 | Recruiting |
| Korea University Anam Hospital | Seoul | Seongbuk-gu, 73 Goryeodae-ro | Recruiting |
More Wonju Severance Christian Hospital trials in South Korea
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06250712 on ClinicalTrials.gov ↗ ← All trials in South Korea